| Market Cap | 17.22B | P/E | 25.46 | EPS this Y | 1.20% | Ern Qtrly Grth | -4.80% |
| Income | 642.23M | Forward P/E | 21.58 | EPS next Y | 10.50% | 50D Avg Chg | 9.00% |
| Sales | 2.96B | PEG | 4.99 | EPS past 5Y | 9.99% | 200D Avg Chg | -4.00% |
| Dividend | N/A | Price/Book | 22.34 | EPS next 5Y | 5.04% | 52W High Chg | -18.00% |
| Recommedations | 3.00 | Quick Ratio | 1.39 | Shares Outstanding | 59.31M | 52W Low Chg | 18.00% |
| Insider Own | 0.06% | ROA | 13.54% | Shares Float | 59.05M | Beta | 0.96 |
| Inst Own | 101.93% | ROE | 77.62% | Shares Shorted/Prior | 3.79M/3.75M | Price | 291.77 |
| Gross Margin | 59.57% | Profit Margin | 21.72% | Avg. Volume | 632,741 | Target Price | 327.14 |
| Oper. Margin | 36.96% | Earnings Date | May 7 | Volume | 1,400,324 | Change | 6.33% |
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.
| Evercore ISI Group | In-Line | Apr 4, 24 |
| Barclays | Underweight | Feb 12, 24 |
| Stifel | Hold | Feb 7, 24 |
| Barclays | Underweight | Jan 25, 24 |
| Wolfe Research | Peer Perform | Dec 13, 23 |
| Citigroup | Neutral | Dec 11, 23 |
| Barclays | Underweight | Nov 13, 23 |
| Stifel | Hold | Nov 8, 23 |
| JP Morgan | Neutral | Nov 8, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| KUEBLER CHRISTOPHER A | Director Director | Aug 04 | Sell | 291.48 | 4,000 | 1,165,920 | 14,382 | 08/07/23 |
| KUEBLER CHRISTOPHER A | Director Director | Aug 04 | Option | 99.22 | 4,000 | 396,880 | 18,382 | 08/07/23 |
| CONARD EDWARD | Director Director | Nov 30 | Option | 335.42 | 4,000 | 1,341,680 | 75,283 | 12/01/22 |
| CONARD EDWARD | Director Director | Nov 30 | Sell | 334.7 | 1,059 | 354,447 | 74,224 | 12/01/22 |
| KUEBLER CHRISTOPHER A | Director Director | May 19 | Option | 88.71 | 4,000 | 354,840 | 18,064 | 05/23/22 |
| KUEBLER CHRISTOPHER A | Director Director | May 19 | Sell | 328.78 | 4,000 | 1,315,120 | 14,064 | 05/23/22 |
| Hendrickson Gary E | Director Director | May 05 | Sell | 335.74 | 5,962 | 2,001,682 | 2,283 | 05/09/22 |
| Hendrickson Gary E | Director Director | May 05 | Option | 335.69 | 5,962 | 2,001,384 | 8,245 | 05/09/22 |
| BADDOUR LINDA | Director Director | Aug 17 | Sell | 408.99 | 1,260 | 515,327 | 1,797 | 08/17/21 |
| BADDOUR LINDA | Director Director | Aug 17 | Option | 183.41 | 1,260 | 231,097 | 3,057 | 08/17/21 |
| Buck Sherry | SVP and CFO SVP and CFO | Nov 02 | Option | 141.74 | 17,499 | 2,480,308 | 21,219 | 11/02/20 |
| Buck Sherry | SVP and CFO SVP and CFO | Nov 02 | Sell | 221.62 | 17,499 | 3,878,128 | 3,720 | 11/02/20 |